Evidence map›Paper›PMID 31327131›Full record

Trial reportJournal of assisted reproduction and genetics2019

Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.

Mojdeh Bahramrezaie, Fardin Amidi, Ashraf Aleyasin, AboTaleb Saremi, Marzieh Aghahoseini, Samaneh Brenjian, Mahshad Khodarahmian, Arash Pooladi

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of assisted reproduction and genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 7 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 7 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Resveratrol and Female Fertility: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mojdeh BahramrezaieDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Fardin AmidiDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. famidi@sina.tums.ac.ir.ORCID http://orcid.org/0000-0003-1165-5232
Ashraf AleyasinFaculty of Medicine, Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
AboTaleb SaremiSarem Fertility and Infertility Research Center (SAFIR), Sarem Cell Research Center (SCRC), Sarem Women's Hospital, Tehran, Iran.
Marzieh AghahoseiniFaculty of Medicine, Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Samaneh BrenjianDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mahshad KhodarahmianDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Arash PooladiCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Tehran University of Medical Sciences · IRShariati Hospital · IRKurdistan University of Medical Sciences · IRSarem Cell Research Center · IR

Funding

Tehran University of Medical Sciences and Health Services 94-02-30-29469
6 · The paper itself

Abstract

objectivesManagement options for PCOS, as the most prevalent endocrine disorder in women of reproductive age, using natural supplements have a high priority for physicians, especially based on the etiological pathways. Therefore, this study was conducted to describe the effect of resveratrol on the angiogenesis pathway, for management of PCOS through assessing VEGF, HIF1 gene expression, and laboratory parameters.

methodsIn this triple-blind RCT, PCOS was confirmed in ICSI candidates based on the Rotterdam criteria. Sixty-two patients that met the inclusion criteria were randomly assigned to two groups. All patients took resveratrol 800 mg/day or placebo for 40 days orally from the beginning of their previous menstruation cycle until the oocyte retrieval day. The serum levels of different hormones were measured, and the expression of HIF1 & VEGF genes was quantified by real-time PCR.

resultsAs for the laboratory hormone assay in 61 PCOS patients, a significant mean difference was seen in the FSH, LH, TSH, and testosterone between the two groups (P < 0.05). The results showed a reduction in the expression of VEGF & HIF1 genes under the effect of resveratrol in the granulosa cells (P = 0.0001). The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05).

conclusionsBased on the results, resveratrol may improve some outcomes of PCOS patients, probably through changing the serum levels of some sex hormones and expression of VEGF & HIF1 genes in the angiogenesis pathway of granulosa cells.

Indexed as

AdolescentAdultAntioxidantsCells, CulturedFemaleGene Expression RegulationGranulosa CellsHumansHypoxia-Inducible Factor 1, alpha SubunitOocyte RetrievalPolycystic Ovary SyndromeResveratrolSperm Injections, IntracytoplasmicVascular Endothelial Growth Factor AYoung AdultAntioxidantsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitResveratrolVascular Endothelial Growth Factor AVEGFA protein, humanHIF1 geneHormonesIntracytoplasmic sperm injectionPolycystic ovary syndromeResveratrolVEGF gene

Identifiers

PMID31327131
PMCPMC6708036
OpenAlexW2963061362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.